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ABSTRACT
Introduction: Photodynamic therapy (PDT) is a
well-established treatment for actinic keratosis
(AK), basal cell carcinoma (BCC), and Bowen’s
disease (BD). The object of this study was to
describe the results of a retrospective analysis of
patients treated with methyl aminolevulinate
PDT (MAL-PDT) with red light, over the past
decade at the Hospital de Braga (Braga,
Portugal).
Methods: This study is based on the
retrospective analysis of the clinical records of
patients treated with MAL-PDT from January
2003 to December 2013.
Results: More than 550 patients with mean age
of 72 years were treated with MAL-PDT. About
two-thirds of these patients were female. In
terms of diagnostics, 67% of the patient
population were affected with AK, 27%
presented with BCC, and 4% had BD. With an
average follow-up of 5.5 years, 99.5% of the
lesions had cleared. The recurrence of lesions
occurred during the first year of follow-up,
mostly large BCC localized on the trunk.
Conclusion: This study showed the excellence
of MAL-PDT for treating AK, BCC, and BD, with
a low recurrence rate.
Keywords: Actinic keratosis; Basal cell
carcinoma; Bowen’s disease; Methyl
aminolevulinate; Photodynamic therapy
INTRODUCTION
Photodynamic therapy (PDT) has been an
important addition to the treatment
modalities available to dermatologists [1–3].
Worldwide it is now a well-established and
approved treatment option for actinic keratosis
(AK) grade I, basal cell carcinoma (BCC), and
also Bowen’s disease (BD), with an
acceptable tolerability profile and few reported
complications [4–6].
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The PDT effect is due to a type II
photochemical reaction, which requires the
presence of a photosensitizing molecule,
photoactivating wavelengths of visible light,
and tissue oxygen to generate singlet oxygen,
which is highly reactive and initiates a series of
reactions that culminate in necrosis and
apoptosis.
Methyl aminolevulinate (MAL) associated to
PDT (MAL-PDT) is approved for superficial skin
malignancies such AK, BCC, and BD. MAL-PDT
is a two-step procedure. In the first step, after a
careful skin preparation, MAL is applied on the
affected area and is allowed to be taken up by
the skin. The application of MAL for 3 h under
occlusion leads to an accumulation of
protoporphyrin IX (PpIX) in the target cells.
The second step involves the activation of PpIX
in the presence of oxygen by directing red light
toward the target tissue. Because the
photosensitizer is preferentially absorbed by
affected tissue and the light source is directly
targeted on the lesion, PDT achieves dual
selectivity, minimizing damage to adjacent
healthy structures.
AK is a precancerous skin condition, which
can progress to invasive squamous cell
carcinoma (SCC) at a yearly rate of
0.075–0.096% per lesion [3]. Patients with
higher risk of developing AK include the
elderly, patients with lighter skin phototypes,
and those with a history of chronic sun
exposure [2, 3]. AK can be treated with PDT on
a lesion-by-lesion basis, or by applying a
photosensitizer in a broad field of actinic
damage, which allows concomitant treatment
of subclinical AK [1–3]. Recently, it was shown
in a retrospective analysis that direct invasion
from proliferating grade I AK could be the most
common form of progression to cutaneous
invasive SCC [1].
Superficial BCC is a common skin tumor, with
incidence increasing worldwide; it is commonly
treated with surgical excision, curettage, or
cryotherapy [4]. PDT has been widely used for
the treatment of BCC in preference to excision,
due to its minimal invasiveness and satisfactory
cosmetic results [3, 4]. Nonetheless, the efficacy
of PDT monotherapy may be reduced in the
treatment of deeper lesions ([2 mm depth) and
more aggressive histological subtypes of BCC [4].
BD is considered an early stage or
intraepidermal form of SCC [5]. PDT is
recommended as the treatment of choice for
both large and small plaques of BD at
poor-healing sites and a good choice for large
lesions at good-healing sites [7–9].
The results reported herein are a
retrospective analysis of the clinical records of
583 patients who over the past decade were
treated with MAL-PDT after being admitted in
the PDT consultation at the Hospital de Braga,
Braga, Portugal (henceforth referred to as ‘‘the
institution’’), a European excellence center for
PDT, where this therapy is routinely used.
METHODS
This retrospective observational study was
performed by analyzing the clinical records of
patients treated with PDT at the institution, in
the period from January 1, 2003 to December
31, 2013. Each patient was characterized in
terms of age, gender, ethnicity, diagnosis, and
number and size of lesions.
At baseline, dermatologic examination was
performed in all patients with a clinical diagnosis
of AK, BCC, or BD. Only patients with histological
confirmation of superficial BCC or BD were
included in the study. The diagnosis of AK was
based only on clinical examination. The patients
presenting nodular or morpheaform BCC were
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excluded. Informedconsentwasobtainedfromall
patients before treatment with PDT. All
procedures followed were in accordance with the
ethical standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013.
Prior to application of MAL cream, all lesions
foreseen for treatment were prepared and crusts
and scales were gently removed, always by a
dermatologist experienced in PDT.
Subsequently, a 1-mm-thick layer of MAL
160 mg/g cream was applied for 3 h under an
occlusive film dressing. MAL was removed after
3 h incubation time and the skin was exposed to
630 nm red light from a diode lamp, with a total
radiation dose of 37 J/cm2 during 7 min.
A protocol of two treatments performed
1 week apart for all lesions was used, this
being one cycle. All patients were evaluated
3 months after the first cycle, and only if
required they were submitted to a new cycle.
Patients with complete resolution after the
3-month follow-up were further regularly
checked during a follow-up of at least
12 months in the cases of AK, and a minimum
of 5 years in the cases of BCC and BD. The
5-year follow-up routine consisted of
dermatologic consultations twice a year during
the first 2 years after diagnosis and then every
12 months in the last 3 years. The recurrences of
lesions were treated with an extra cycle of PDT
or with conventional surgery. The record of
every patient also included information about
safety, tolerability, and satisfaction with PDT.
RESULTS
Population
In total, 583 patients were considered in the
study and 1969 lesions were treated with
MAL-PDT. Of these patients, 62.6% (n = 365)
were female and 37.4% (n = 218) were male.
The mean age of the patients was 72.3 years
(range 17–103 years). Patients were all of
Caucasian origin. Furthermore, 67.4%
(n = 393) were affected with AK, 28.6%
(n = 167) presented BCC, and 2.7% (n = 16)
had BD. Figures 1 and 2 show two examples of
patients treated with PDT.
Type of Lesions
With respect to the treated lesions, 79.1%
(n = 1558) were AK 17.98% (n = 354) were
BCC and 1.48% (n = 23) were BD. All patients
with AK had multiple lesions. Previous
treatment modalities included keratolytics and
cryotherapy.
Location of Lesions
The locations of treated AK lesions were
predominantly on the face (66.2%, n = 1032)
and on the bald scalp (12.5%, n = 194; Table 1).
BCC predominantly affected the face (42.4%,
n = 150) and the trunk (37.1%, n = 131). BD
predominantly affected the legs (47.8%, n = 11)
and the face (43.5%, n = 10).
In female patients with AK, the median age
of the patients was 77 years. For BCC, the
median age of the patients was 69 years. In the
male patient population with AK, the median
age of the patients was 76 years, those with BCC
had a median age of 68 years. It was statistically
confirmed that the distribution of lesions by
diagnosis was not independent of sex
(X2 = 18.2; P\0.01).
In female patients, 72.1% (n = 695) of AK
and 50.8% (n = 97) of BCC are located on the
face. In male patients, 30.0% (n = 175) of AK are
located on the scalp and 41.1% (n = 67) of BCC
are located on the trunk (Fig. 3). It was also
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observed that the distribution of lesions by
localization was not independent of sex in both
cases of AK (X2 = 294.3; P\0.001) and
BCC (X2 = 18.9; P\0.01).
Diagnosis of Lesions
Among our cohort of patients, 546 had only 1
diagnosis and 37 had at least 2 diagnoses. In
patients with multiple diagnoses, the most
frequent association observed was AK and BCC
in 86.5% (n = 37). The size of the lesions in the
period covered by this analysis was of median
area of 25 mm2 in the cases of AK and 20 mm2
in BCC.
Side Effects of PDT
Apart from mild pain during the red light
illumination, which was minimized by the
Fig. 1 A basal cell carcinoma localized on the antihelix of the ear and treated with photodynamic therapy. a Lesion before
treatment. b Follow-up after 5 years
Fig. 2 Multiple actinic keratosis localized on the bald scalp and treated with photodynamic therapy. a Lesions before
treatment. b Follow-up after 5 years
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presence of a nurse and the soothing effect of an
in-house-designed music program, there were
no other adverse effects of PDT in the patients.
All patients showed good compliance with the
treatment and expressed signs of satisfaction.
Follow-up
With an average 5.5-year follow-up, 99.5% of
the lesions were cleared and there was only a
marginal 0.5% of recurrence of lesions all
occurring during the first 6 months. The
recurrence of all lesions occurred during the
first year of follow-up and corresponded to large
BCC localized on the trunk.
DISCUSSION
The large incidence of AK may be explained by
the weather in Portugal, a country with a
Mediterranean temperate climate, with many
hours of sunshine, this being the major risk
factor for the development of AK lesions. The
predominant phototype in Portugal is
phototype III [10]. These lesions when
localized on the face and scalp respond well to
PDT, with typical clearance rates of 89–92%
[3–9]. The present guidelines for AK therapy
recommend PDT being given as a single
treatment and, if required, repeated 3 months
later [9]. A good preparation of the lesions is
important—removal of crusts and scales—
before MAL cream application, which at the
institution is always done by a PDT-experienced
dermatologist.
PDT was used for the treatment of BCC, with
a clearance rate in accordance with other
studies, namely Morton et al. [9] who reported
92–97%. In this study, it was found that the
most frequent localization of AK in female
patients was on the face and on the scalp for
male patients. The excess of AK on the scalp in
male patients is explained for many of these
patients having a bald scalp, with a
sun-damaged skin, a major risk factor for the
development of AK. Individuals at higher risk of
developing AK were elderly patients, which is
also in accordance with the literature [1, 9, 11,
12].
PDT is an excellent treatment in the cases of
large or multiple BCC because their growth
pattern is primarily horizontal. Therefore, large
scars and complications of conventional surgery
are avoided, with good cosmetic results and
high patient satisfaction [9, 12].
This is a retrospective study, with all
limitations of a study of this type (e.g., the
study population was not previously specified
in terms of age and gender, and also social and
professional background). Nevertheless, it has
Table 1 Lesions by location: cases (%)
Location Total
Face Scalp Trunk Hands Feet Arms Legs
AK 1032 (66.2) 194 (12.5) 13 (0.8) 148 (9.5) 16 (1.0) 68 (4.4) 87 (5.6) 1558 (100)
BCC 150 (42.4) 27 (7.6) 131 (37.1) 2 (0.6) 7 (1.98) 23 (6.5) 14 (3.95) 354 (100)
BD 10 (43.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.7) 0 (0.0) 11 (47.8) 23 (100)
Total 1192 221 144 150 25 91 114 1935
AK actinic keratosis, BCC basal cell carcinoma, BD Bowen’s disease
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Fig. 3 Frequency distribution of a BCC and b AK in patients treated with PDT. AK actinic keratosis, BCC basal cell
carcinoma
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the strength of being the presentation of the
overall experience of a clinical department
where PDT has been applied for over a decade.
CONCLUSIONS
This experience underlines the importance of a
good selection of lesions being performed prior
to PDT, all deeper lesions ([2 mm depth) being
excluded. Also it is the requirement of a good
preparation of lesions, including gentle
removal of scales and crusts, which must
always be done by a dermatologist with a
prior experience with PDT. The excellent
results of PDT during the period from 2003 to
2013 were apparent in a significant population
of patients from the North of Portugal. In
conclusion, MAL-PDT has been an essential
part of the Hospital de Braga armamentarium
in caring for patients with AK, BCC, and BD,
with excellent cosmetic results for the vast
majority of them.
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Musulen E, et al. Actinic keratosis with atypical
basal cells (AK I) is the most common lesion
associated with invasive squamous cell carcinoma
of the skin. JEADV. 2015;29:991–7.
2. Calzavara-Pinton PG, Rossi MT, Sala R, Italian Group
for Photodynamic Therapy. A retrospective analysis
of real-life practice of off-label photodynamic
therapy using methyl aminolevulinate (MAL-PDT)
in 20 Italian dermatology departments. Part 2:
oncologic and infectious indications. Photochem
Photobiol Sci. 2013;12:158–65.
3. Criscione VD, Weinstock MA, Naylor MF, Lugue C,
Eide MJ, et al. Actinic keratosis: natural history and
risk of malignant transformation in the Veterans
Affairs Tropical Tretinoin Chemoprevention Trial.
Cancer. 2009;115:2523–30.
4. Trakatelli M, Morton C, Nagore E, Ulrich C, Del
Marmol V. Update of the European guidelines for
basal cell carcinoma management. Eur J Dermatol.
2014;24(3):312–29.
Dermatol Ther (Heidelb)
5. Klein A, Babilas P, Karrer S, Landthaler M, Szeimies
RM, et al. Photodynamic therapy in dermatology—
an update 2008. JDDG. 2008;6:839–45.
6. Babilas P, Landthaler M, Szeimies RM.
Photodynamic therapy in dermatology. Eur J
Dermatol. 2006;16:340–8.
7. Fai D, Arpaia N, Romano I, Vestita M, et al.
Methyl-aminolevulinate photodynamic therapy
for the treatment of actinic keratoses and
non-melanoma skin cancers: a retrospective
analysis of response in 462 patients. G Ital
Dermatol Venereol. 2009;144:281–5.
8. Vergilis-Kalner IJ, Cohen JL. The use of
photodynamic therapy as chemoprevention for
the treatment of actinic keratoses and reduction
in the number of non-melanoma skin cancers.
J Drugs Dermatol. 2013;12:1085–6.
9. Morton CA, Szeimies RM, Sidoroff A, Braathen LR.
European guidelines for topical photodynamic
therapy part 1: treatment delivery and current
indications—actinic keratoses, Bowen’s disease,
basal cell carcinoma. JEADV. 2013;27:536–44.
10. Brasileiro A, Campos S, Rocha-Páris F, Fidalgo A,
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